Marsh J C
Department of Haematology, St. George Hospital Medical School, London, UK.
Acta Haematol. 2000;103(1):26-32. doi: 10.1159/000041001.
The availability of immunosuppressive agents, such as antilymphocyte globulin and cyclosporin, has had a major impact on the outcome of patients with aplastic anaemia. The majority of patients will show a response to immunosuppressive therapy. For those who fail to respond to an initial course, a second or further courses of immunosuppression can be given. Improvement in survival may also be due to the improved quality of supportive care available today for patients with aplastic anaemia. The additional use of haemopoietic growth factors such as granulocyte colony stimulating factor with immunosuppressive therapy requires further prospective randomised studies in order to evaluate whether they are of benefit for patients with aplastic anaemia. Because of the rarity of this condition, the use of multicentre prospective randomised studies is crucial for further evaluation of treatment modalities in aplastic anaemia.
免疫抑制剂如抗淋巴细胞球蛋白和环孢素的应用，对再生障碍性贫血患者的治疗结果产生了重大影响。大多数患者对免疫抑制治疗会有反应。对于那些对初始疗程无反应的患者，可以给予第二个或更多疗程的免疫抑制治疗。生存率的提高也可能归因于如今再生障碍性贫血患者可获得的支持性护理质量的改善。免疫抑制治疗联合使用造血生长因子如粒细胞集落刺激因子，需要进一步的前瞻性随机研究，以评估它们对再生障碍性贫血患者是否有益。由于这种疾病罕见，多中心前瞻性随机研究对于进一步评估再生障碍性贫血的治疗方式至关重要。
